menu
    • menu

    Find Flibanserin manufacturers, exporters & distributors on PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

    Virtual Booth

    Contact Supplier

    Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    8

    API Suppliers

    API Suppliers

    1

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    0

    EU WC

    EU WC

    0

    KDMF

    KDMF

    2

    NDC API

    NDC API

    0

    VMF

    NDC API

    7

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 1,009

    MARKET PLACE

    6

    API

    0

    FDF

    0INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    4

    FDF Dossiers

    FDF Dossiers

    1

    FDA Orange Book

    FDA (Orange Book)

    1

    Europe

    Europe

    1

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    1

    Listed Dossiers

    Listed Dossiers

    1DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    PATENTS & EXCLUSIVITIES

    1

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    2

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    18

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    NA

    Finished Drug Prices

    NA

    159 RELATED EXCIPIENT COMPANIES

    247EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 167933-07-5, Bimt-17, Bimt 17, Addyi, Ectris, Girosa
    Molecular Formula
    C20H21F3N4O
    Molecular Weight
    390.4  g/mol
    InChI Key
    PPRRDFIXUUSXRA-UHFFFAOYSA-N
    FDA UNII
    37JK4STR6Z
    Flibanserin
    Flibanserin is an orally bioavailable, non-hormonal, multifunctional serotonin agonist and antagonist (MSAA) that may improve sexual desire and arousal in women. Upon oral administration, flibanserin selectively binds to serotonin receptors in the central nervous system, acting as an agonist on 5-HT1A receptors and an antagonist on 5-HT2A receptors. Agonist activity at 5-HT1A postsynaptic receptors may enhance the release of dopamine and other monoamines. Combined with 5-HT2A antagonism, flibanserin boosts levels of dopamine in the mesocortical area of the prefrontal cortex and produces a net increase of norepinephrine selectively in the prefrontal cortex through disinhibition of locus coeruleus noradrenergic neurons. In addition, flibanserin reduces concentrations of serotonin in the prefrontal cortex with chronic administration. Reducing serotonin, which modulates sexual activity in an inhibitory fashion through downstream decreases in dopamine release, while enhancing the release of norepinephrine and dopamine in the prefrontal cortex may improve sexual desire and interest.
    The mechanism of action of flibanserin is as a P-Glycoprotein Inhibitor.
    1 2D Structure

    Flibanserin

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    3-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one
    2.1.2 InChI
    InChI=1S/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28)
    2.1.3 InChI Key
    PPRRDFIXUUSXRA-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=CC(=C4)C(F)(F)F
    2.2 Other Identifiers
    2.2.1 UNII
    37JK4STR6Z
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 1-(2-(4-(3-trifluoromethylphenyl)piperazin-1-yl)ethyl)benzimidazol(1h)-2-one

    2. Addyi

    3. Bimt 17

    4. Bimt-17

    2.3.2 Depositor-Supplied Synonyms

    1. 167933-07-5

    2. Bimt-17

    3. Bimt 17

    4. Addyi

    5. Ectris

    6. Girosa

    7. Bimt 17 Bs

    8. Bimt-17-bs

    9. Filbanserin.

    10. 1-(2-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)ethyl)-1h-benzo[d]imidazol-2(3h)-one

    11. 1,3-dihydro-1-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)-2h-benzimidazol-2-one

    12. 37jk4str6z

    13. Female Viagra [street Name]

    14. 3-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1h-benzimidazol-2-one

    15. 2h-benzimidazol-2-one, 1,3-dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-

    16. 1-(2-(4-(3-trifluoromethylphenyl)piperazin-1-yl)ethyl)benzimidazol(1h)-2-one

    17. Female Viagra (street Name)

    18. Flibanserin [usan]

    19. 1,3-dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-2h-benzimidazol-2-one

    20. Flibanserin [usan:inn]

    21. Unii-37jk4str6z

    22. Addyi (tn)

    23. Flibanserin [mi]

    24. Flibanserin [inn]

    25. Flibanserin (usan/inn)

    26. Bimt 17bs

    27. Bimt-17bs

    28. 1-(2-(4-alpha,alpha,alpha-trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone

    29. Flibanserin [mart.]

    30. Flibanserin [who-dd]

    31. Girosa (proposed Trade Name)

    32. Schembl247579

    33. Chembl231068

    34. Gtpl8182

    35. Chebi:90865

    36. Hsdb 8278

    37. Flibanserin [orange Book]

    38. Hms3885k21

    39. Bcp02131

    40. Ex-a2807

    41. Hy-a0095

    42. Bdbm50476735

    43. Mfcd00918402

    44. S3716

    45. Zinc52716421

    46. Akos005146139

    47. Flibanserin; Bimt-17; Bimt-17bs

    48. Am84577

    49. Ccg-268528

    50. Cs-4671

    51. Db04908

    52. 1-(2-(4-(alpha,alpha,alpha-trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone

    53. 2h-benzimidazol-2-one,1,3-dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-

    54. Ncgc00386567-01

    55. Ncgc00386567-02

    56. Ncgc00386567-03

    57. F1239

    58. Ft-0659246

    59. D02577

    60. 933f075

    61. A810922

    62. L001463

    63. Q415996

    64. 1-(2-(4-alpha,alpha,alpha-trifluoro-m-tolyl)-1-(piperazinyl)ethyl)-2-benzimidazolinone

    65. 1-[2-[4-(3-trifluoromethylphenyl)piperazin-1-yl]ethyl]benzimidazol-[1h]-2-one

    66. 3-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-1h-benzimidazol-2-one

    67. 1-(2-(4-(.alpha.,.alpha.,.alpha.-trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone

    68. 1-(2-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}ethyl)-1,3-dihydro-2h-benzimidazol-2-one

    2.4 Create Date
    2006-07-28
    3 Chemical and Physical Properties
    Molecular Weight 390.4 g/mol
    Molecular Formula C20H21F3N4O
    XLogP33.3
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count4
    Exact Mass390.16674579 g/mol
    Monoisotopic Mass390.16674579 g/mol
    Topological Polar Surface Area38.8 Ų
    Heavy Atom Count28
    Formal Charge0
    Complexity550
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Therapeutic Uses

    /CLINICAL TRIALS/ ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. The Web site is maintained by the National Library of Medicine (NLM) and the National Institutes of Health (NIH). Each ClinicalTrials.gov record presents summary information about a study protocol and includes the following: Disease or condition; Intervention (for example, the medical product, behavior, or procedure being studied); Title, description, and design of the study; Requirements for participation (eligibility criteria); Locations where the study is being conducted; Contact information for the study locations; and Links to relevant information on other health Web sites, such as NLM's MedlinePlus for patient health information and PubMed for citations and abstracts for scholarly articles in the field of medicine. Flibanserin is included in the database.

    NIH/NLM; ClinicalTrials.Gov. Available from, as of September 30, 2015: https://clinicaltrials.gov/search/intervention=FLIBANSERIN%20OR%20BIMT-17

    Addyi is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: A co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance. Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire. Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation or partner. /Included in US product label/

    NIH; DailyMed. Current Medication Information for Addyi (Flibanserin) Tablet, Film Coated (Updated: August 2015). Available from, as of November 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394

    EXPL THER A central problem in the treatment of Parkinson's disease (PD) is the development of motor disturbances like L-DOPA-induced dyskinesia (LID) after long-term treatment. Preclinical and clinical studies demonstrated that serotonin 5-HT(1A) receptor agonists attenuate this disabling motor side effect. The aim of this study was to investigate the ability of flibanserin compared to buspirone to attenuate L-DOPA-sensitized contraversive circling in hemiparkinsonian rats, which is an animal model of LID. Both drugs have a preferential affinity for the serotonin 5-HT(1A) receptors. Buspirone was in comparison because it was expected to have an effect in this model. Unilaterally 6-hydroxydopamine lesioned rats were treated twice daily intraperitoneally (ip) with L-DOPA methylester (12.5 mg/kg) and benserazide (3.25 mg/kg) for 21 days (on days 1, 3, 5, 8, 11, 14, 17 and 21). On day 24, L-DOPA-sensitized rats were treated ip 5 min prior to administration of L-DOPA methyl ester and benserazide with either saline (controls), 2.5, 5 and 10 mg/kg buspirone or flibanserin. Acute administration of both flibanserin and buspirone, dose dependently, attenuated the increased contraversive circling. An almost complete inhibition of the turning response was observed at 5 mg/kg buspirone and 10 mg/kg flibanserin. The current preclinical findings further implicate the 5-HT(1A) receptor as a promising therapeutic target for the reduction of LID and predict a potential efficacy of flibanserin in the treatment of LID in PD.

    PMID:21274579 Gerlach M et al; J Neural Transm 118(12): 1727-32 (2011).

    4.2 Drug Warning

    /BOX WARNING/ The use of Addyi in patients with hepatic impairment increases flibanserin concentrations, which can cause severe hypotension and syncope. Therefore, Addyi is contraindicated in patients with hepatic impairment. Inhibitors are contraindicated in patients taking Addyi.

    NIH; DailyMed. Current Medication Information for Addyi (Flibanserin) Tablet, Film Coated (Updated: August 2015). Available from, as of November 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394

    /BOX WARNING/ The concomitant use of Addyi and moderate or strong CYP3A4 inhibitors increase s flibanserin concentrations, which can cause severe hypotension and syncope. Therefore, the use of moderate or strong CYP3A4 inhibitors is contraindicated in patients taking Addyi.

    NIH; DailyMed. Current Medication Information for Addyi (Flibanserin) Tablet, Film Coated (Updated: August 2015). Available from, as of November 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394

    /BOX WARNING/ The use of Addyi and alcohol increases the risk of severe hypotension and syncope. Therefore, alcohol use is contraindicated in patients taking Addyi. Before prescribing Addyi, assess the likelihood of the patient abstaining from alcohol, taking into account the patient's current and past drinking behavior, and other pertinent social and medical history. Counsel patients who are prescribed Addyi about the importance of abstaining from alcohol use. Because of the increased risk of hypotension and syncope due to an interaction with alcohol, Addyi is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Addyi REMS Program.

    NIH; DailyMed. Current Medication Information for Addyi (Flibanserin) Tablet, Film Coated (Updated: August 2015). Available from, as of November 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394

    Addyi can cause CNS depression (e.g., somnolence, sedation). In five 24-week, randomized, placebo controlled, double-blind trials of premenopausal women with hypoactive sexual desire disorder (HSDD), the incidence of somnolence, sedation or fatigue was 21% and 8% in patients treated with 100 mg Addyi once daily at bedtime and placebo, respectively. The risk of CNS depression is increased if Addyi is taken during waking hours, or if Addyi is taken with alcohol or other CNS depressants, or with medications that increase flibanserin concentrations, such as CYP3A4 inhibitors.

    NIH; DailyMed. Current Medication Information for Addyi (Flibanserin) Tablet, Film Coated (Updated: August 2015). Available from, as of November 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394

    For more Drug Warnings (Complete) data for Flibanserin (9 total), please visit the HSDB record page.

    4.3 Drug Indication

    For the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.

    FDA Label

    Hypoactive Sexual Desire Disorder in Women

    5 Pharmacology and Biochemistry
    5.1 FDA Pharmacological Classification
    5.1.1 Active Moiety
    FLIBANSERIN
    5.1.2 FDA UNII
    37JK4STR6Z
    5.1.3 Pharmacological Classes
    P-Glycoprotein Inhibitors [MoA]
    5.2 ATC Code

    G - Genito urinary system and sex hormones

    G02 - Other gynecologicals

    G02C - Other gynecologicals

    G02CX - Other gynecologicals

    G02CX02 - Flibanserin

    5.3 Absorption, Distribution and Excretion

    Absorption

    Flibanserin has an absolute oral availability of 33%.

    Route of Elimination

    Elimination via feces (51%) and urine (44%) following a single oral 50 mg dose of flibanserin solution.

    Approximately 98% of the drug is bound to human serum proteins, mainly to albumin.

    NIH; DailyMed. Current Medication Information for Addyi (Flibanserin) Tablet, Film Coated (Updated: August 2015). Available from, as of November 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394

    Food increased the extent of absorption and slowed the rate of absorption of a 50 mg dose of flibanserin (one half the recommended dosage). Low-, moderate-, and high-fat meals increased flibanserin AUC0-inf by 1.18-, 1.43-, and 1.56-fold; increased Cmax by 1.02-, 1.13-, and 1.15-fold; and prolonged median Tmax to 1.5, 0.9, 1.8 hours from 0.8 hours under fasted conditions, respectively.

    NIH; DailyMed. Current Medication Information for Addyi (Flibanserin) Tablet, Film Coated (Updated: August 2015). Available from, as of November 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394

    Following oral ministration of a single 100 mg dose of flibanserin in healthy premenopausal women (N=8), mean (SD) Cmax was 419 (206) ng/mL and mean (SD) AUC0-inf was 1543 (511) ng*hr/mL. Median (range) time to reach Cmax was 0.75 (0.75 to 4.0) hours. Absolute bioavailability of flibanserin following oral dosing is 33%.

    NIH; DailyMed. Current Medication Information for Addyi (Flibanserin) Tablet, Film Coated (Updated: August 2015). Available from, as of November 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394

    /MILK/ Flibanserin is excreted in rat milk. It is unknown whether flibanserin is present in human milk, ... .

    NIH; DailyMed. Current Medication Information for Addyi (Flibanserin) Tablet, Film Coated (Updated: August 2015). Available from, as of November 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394

    5.4 Metabolism/Metabolites

    Metabolism is primarily via CYP3A4, slightly CYP2C19. Minimal involvement of CYP1A2, CYP2B6, CYP2C8, CYP2C9 or CYP2D6. At least 35 metabolites of flibanserin are produced, 2 of which reach plasma concentrations as high as parent drug, however they are pharmacologically inactive.

    Flibanserin is primarily metabolized by CYP3A4 and, to a lesser extent, by CYP2C19. Based on in vitro and/or in vivo data, CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP2D6 contribute minimally to the metabolism of flibanserin. After a single oral solution dose of 50 mg 14C-radiolabeled flibanserin, 44% of the total 14C-flibanserin related radioactivity was recovered in urine, and 51% was recovered in feces. Flibanserin is extensively metabolized to at least 35 metabolites, most of them occurring in low concentrations in plasma. Two metabolites could be characterized that showed plasma concentrations similar to that achieved with flibanserin: 6,21-dihydroxy-flibanserin-6,21-disulfate and 6-hydroxy-flibanserin-6-sulfate. These two metabolites are inactive.

    NIH; DailyMed. Current Medication Information for Addyi (Flibanserin) Tablet, Film Coated (Updated: August 2015). Available from, as of November 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394

    5.5 Biological Half-Life

    11 hours

    Flibanserin has a mean terminal half-life of approximately 11 hours.

    NIH; DailyMed. Current Medication Information for Addyi (Flibanserin) Tablet, Film Coated (Updated: August 2015). Available from, as of November 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394

    5.6 Mechanism of Action

    Flibansetrin has high affinity for serotonin receptors in the brain: it acts as an agonist on 5-HT1A and an antagonist on 5-HT2A. In vivo, flibanserin binds equally to 5-HT1A and 5-HT2A receptors. However, under higher levels of brain 5-HT (i.e., under stress), flibanserin may occupy 5-HT2A receptors in higher proportion than 5-HT(1A) receptors. It may also moderately antagonize D4 (dopamine) receptors and 5-HT2B and 5-HTB2C. Its action on neurotransmitter receptors may contribute to reduction in serotonin levels and increase in dopamine and norepinephrine levels, all of which may play part in reward processing.

    Flibanserin has preferential affinity for serotonin 5-HT(1A), dopamine D(4k), and serotonin 5-HT(2A) receptors. In vitro and in microiontophoresis, flibanserin behaves as a 5-HT(1A) agonist, a very weak partial agonist on dopamine D(4) receptors, and a 5-HT(2A) antagonist. In vivo flibanserin binds equally to 5-HT(1A) and 5-HT(2A) receptors. However, under higher levels of brain 5-HT (i.e., under stress), flibanserin may occupy 5-HT(2A) receptors in higher proportion than 5-HT(1A) receptors. The effects of flibanserin on adenylyl cyclase are different from those of buspirone and 8-OH-DPAT, two other purported 5-HT(1A) receptor agonists. Flibanserin reduces neuronal firing rate in cells of the dorsal raphe, hippocampus, and cortex with the CA1 region being the most sensitive in the brain. Flibanserin-induced reduction in firing rate in the cortex seems to be mediated through stimulation of postsynaptic 5-HT(1A) receptors, whereas the reduction of the number of active cells seems to be mediated through dopamine D(4) receptor stimulation. Flibanserin quickly desensitizes somatic 5-HT autoreceptors in the dorsal raphe and enhances tonic activation of postsynaptic 5-HT(1A) receptors in the CA3 region. Flibanserin preferentially reduces synthesis and extracellular levels of 5-HT in the cortex, where it enhances extracellular levels of NE and DA. Flibanserin displays antidepressant-like activity in most animal models sensitive to antidepressants. Such activity, however, seems qualitatively different from that exerted by other antidepressants. Flibanserin seems to act via direct or indirect stimulation of 5-HT(1A), DA, and opioid receptors in those animal models. Flibanserin does not display consistent effects in animal models of anxiety and seems to exert potential antipsychotic effects. Flibanserin may induce some sedation but does not induce observable toxic effects at pharmacologically relevant doses.

    PMID:12177684 Borsini F et al; CNS Drug Rev 8(2): 117-42 (2002).

    Flibanserin is a novel pharmacologic agent in late-stage clinical testing for hypoactive sexual desire disorder (HSDD) in premenopausal women. A literature review was conducted of all published works on flibanserin and on related studies of serotonin (5-HT)(1A) receptors and 5-HT(2A) receptors, including their actions on monoamines and on sexual function. At clinically relevant doses, flibanserin acts predominantly at 5-HT(1A) receptors as an agonist and secondarily at 5-HT(2A) receptors as an antagonist. Additional binding actions within an order of magnitude of its 5-HT(1A) affinity, which are not likely to be clinically relevant, include weaker antagonist actions at 5-HT(2C) and 5-HT(2B) receptors, and less defined activity at dopamine (DA) D4 receptors. The 5-HT(1A) actions of flibanserin are only seen postsynaptically, which is unlike other agents such as buspirone that act at presynaptic 5-HT(1A) receptors. Furthermore, the postsynaptic actions of chronic flibanserin administration appear to demonstrate a preference for some populations of postsynaptic 5-HT receptors, particularly those that are located on the prefrontal cortex (PFC) pyramidal neurons, which regulate monoamine release in certain selective brain regions. The regional selectivity of flibanserin results in a unique pattern of monoamine modulation. Sustained increases in baseline of DA and norepinephrine (NE) are observed in the PFC, and flibanserin dosing increases DA and NE levels above the basal changes. Conversely, flibanserin induces transient decreases in 5-HT levels in some brain areas such as the PFC, nucleus accumbens, and hypothalamus, but not in other brain areas such as the hippocampus. Therefore, since DA and NE are excitatory and 5-HT is inhibitory to sexual desire and arousal, it is tempting to postulate that the actions of flibanserin on serotonin receptors at the PFC pyramidal neurons, resulting in increased DA and NE yet reduced 5-HT in the PFC, are the mechanistic underpinnings of enhancing sexual desire in HSDD.

    PMID:20840530 Stahl SM et al; J Sex Med 8(1):15-27 (2011).

    In vitro, flibanserin demonstrated high affinity for the following serotonin (5-hydroxytryptamine or 5-T) receptors: agonist activity at 5-HT1A and antagonist activity at 5-HT2A. Flibanserin also has moderate antagonist activities at the 5-HT2B, 5-HT2C, and dopamine D4 receptors.

    NIH; DailyMed. Current Medication Information for Addyi (Flibanserin) Tablet, Film Coated (Updated: August 2015). Available from, as of November 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1630866600,"product":"FLIBANSERIN","address":"425\/3 RT D NO 7-1-621\/328,S.R.NAGAR","city":"HYDERABAD.AP","supplier":"RAKSHIT PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"TO THE ORDER OF","customerCountry":"TURKEY","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"1490","totalValueFC":"4364","currency":"USD","unitRateINR":107000,"date":"06-Sep-2021","totalValueINR":"321000","totalValueInUsd":"4364","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"4396735","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"425\/3 RT D NO 7-1-621\/328,S.R.NAGAR, HYDERABAD.AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1632508200,"product":"FLIBANSERIN (MICRONISED)","address":"406,WORLD TRADE CENTRE,SAYAJIGUNJ,","city":"VADODARA GUJ.","supplier":"CENTURY PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"DUBLIN","customer":"INOVA PHARMA & LIFE SCINCES","customerCountry":"IRELAND","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"1150","totalValueFC":"5397.2","currency":"USD","unitRateINR":79400,"date":"25-Sep-2021","totalValueINR":"397000","totalValueInUsd":"5397.2","indian_port":"AHMEDABAD AIR","hs_no":"29335990","bill_no":"4847503","productDescription":"API","marketType":"REGULATED MARKET","country":"IRELAND","selfForZScoreResived":"Micronized","supplierPort":"AHMEDABAD AIR","supplierAddress":"406,WORLD TRADE CENTRE,SAYAJIGUNJ,, VADODARA GUJ.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1637087400,"product":"FLIBANSERING IHS ALONG WITH 500 MG WORKI","address":"406,WORLD TRADE CENTRE,SAYAJIGUNJ,","city":"VADODARA GUJ.","supplier":"CENTURY PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"SANAA","customer":"SHIBA PHARMACEUTICALS & ","customerCountry":"YEMEN","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"1600","totalValueFC":"1772.5","currency":"EUR","unitRateINR":132000,"date":"17-Nov-2021","totalValueINR":"132000","totalValueInUsd":"1772.5","indian_port":"AHMEDABAD AIR","hs_no":"29335990","bill_no":"6047033","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"YEMEN, DEMOCRATIC","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"406,WORLD TRADE CENTRE,SAYAJIGUNJ,, VADODARA GUJ.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1656095400,"product":"FLIBANSERIN","address":"425\/3 RT D NO 7-1-621\/328, S.R.NAGAR Contact No: 919177739734","city":"HYDERABAD","supplier":"RAKSHIT PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"SOUTHEAST BANK LIMI","customerCountry":"BANGLADESH","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"980","totalValueFC":"9677.6","currency":"USD","unitRateINR":75500,"date":"25-Jun-2022","totalValueINR":"755000","totalValueInUsd":"9677.6","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"2376467","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"425\/3 RT D NO 7-1-621\/328, S.R.NAGAR Contact No: 919177739734, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1662489000,"product":"FLIBANSERIN","address":"425\/3 RT D NO 7-1-621\/328, S.R.NAGAR Contact No: 919177739734","city":"HYDERABAD","supplier":"RAKSHIT PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"AL ARAFAH ISLAMI ","customerCountry":"BANGLADESH","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"970","totalValueFC":"9508.2","currency":"USD","unitRateINR":76200,"date":"07-Sep-2022","totalValueINR":"762000","totalValueInUsd":"9508.2","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"4020332","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"425\/3 RT D NO 7-1-621\/328, S.R.NAGAR Contact No: 919177739734, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1669314600,"product":"FLIBANSERIN (TAX INVOICE NO:22-23\/EXP-72","address":"H.NO. 8-2-293\/174\/3, ROAD NO. 14,, B.N. REDDY COLONY, BANJARA HILLS,","city":"HYDERABAD,TELANGANA","supplier":"SYMED LABS","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"BEACON PHARMACEUTICALS LIMITED","customerCountry":"BANGLADESH","quantity":"0.80","actualQuantity":"0.8","unit":"KGS","unitRateFc":"937.5","totalValueFC":"686.2","currency":"USD","unitRateINR":70000,"date":"25-Nov-2022","totalValueINR":"56000","totalValueInUsd":"686.2","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"5729340","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"H.NO. 8-2-293\/174\/3, ROAD NO. 14,, B.N. REDDY COLONY, BANJARA HILLS,, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1677781800,"product":"FLIBANSERIN IHS BATCH NO.: 11262001-FBS","address":"309,3RD FLOOR,TIMES TRADE CENTER,B RTS ROAD, PUNAGAM","city":"SURAT,GUJARAT","supplier":"ATOM PHARMA","supplierCountry":"INDIA","foreign_port":"TASHKENT","customer":"TO THE ORDER OF","customerCountry":"UZBEKISTAN","quantity":"0.05","actualQuantity":"0.05","unit":"KGS","unitRateFc":"10000","totalValueFC":"498.5","currency":"USD","unitRateINR":820000,"date":"03-Mar-2023","totalValueINR":"41000","totalValueInUsd":"498.5","indian_port":"AHMEDABAD AIR","hs_no":"29335990","bill_no":"8220181","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UZBEKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"309,3RD FLOOR,TIMES TRADE CENTER,B RTS ROAD, PUNAGAM, SURAT,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1695234600,"product":"FLIBANSERIN (TAX INVOICE NO:23-24\/EXP-497, DT:12-09-2023)","address":"8-3-166\/6 7, IIND FLOOR,SREE ARCADE","city":"HYDERABAD-AP","supplier":"SYMED LABS","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"TO THE ORDER OF","customerCountry":"TURKEY","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"2535","totalValueFC":"2481.7","currency":"USD","unitRateINR":206000,"date":"21-Sep-2023","totalValueINR":"206000","totalValueInUsd":"2481.7","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"4082489","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"8-3-166\/6 7, IIND FLOOR,SREE ARCADE, HYDERABAD-AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1716748200,"product":"FLIBANSERIN","address":"425\/3 RT D NO 7-1-621\/328,","city":"HYDERABAD.AP","supplier":"RAKSHIT PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"BEIRUT","customer":"SEDANAH TRADING COMPANY","customerCountry":"LEBANON","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"750","totalValueFC":"7390.5","currency":"USD","unitRateINR":61602.548999999999,"date":"27-May-2024","totalValueINR":"616025.49","totalValueInUsd":"7390.5","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"1206242","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"LEBANON","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"425\/3 RT D NO 7-1-621\/328,, HYDERABAD.AP","customerAddress":""}]
    06-Sep-2021
    27-May-2024
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Coating Systems & Additives

    read-more
    read-more

    Fillers, Diluents & Binders

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Granulation

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Topical

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Vegetarian Capsules

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Parenteral

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    ABOUT THIS PAGE

    Addyi Manufacturers

    A Addyi manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Addyi, including repackagers and relabelers. The FDA regulates Addyi manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Addyi API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Addyi manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    Addyi Suppliers

    A Addyi supplier is an individual or a company that provides Addyi active pharmaceutical ingredient (API) or Addyi finished formulations upon request. The Addyi suppliers may include Addyi API manufacturers, exporters, distributors and traders.

    click here to find a list of Addyi suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    Addyi USDMF

    A Addyi DMF (Drug Master File) is a document detailing the whole manufacturing process of Addyi active pharmaceutical ingredient (API) in detail. Different forms of Addyi DMFs exist exist since differing nations have different regulations, such as Addyi USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A Addyi DMF submitted to regulatory agencies in the US is known as a USDMF. Addyi USDMF includes data on Addyi's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Addyi USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of Addyi suppliers with USDMF on PharmaCompass.

    Addyi NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Addyi as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for Addyi API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture Addyi as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain Addyi and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Addyi NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of Addyi suppliers with NDC on PharmaCompass.

    Addyi GMP

    Addyi Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Addyi GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Addyi GMP manufacturer or Addyi GMP API supplier for your needs.

    Addyi CoA

    A Addyi CoA (Certificate of Analysis) is a formal document that attests to Addyi's compliance with Addyi specifications and serves as a tool for batch-level quality control.

    Addyi CoA mostly includes findings from lab analyses of a specific batch. For each Addyi CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Addyi may be tested according to a variety of international standards, such as European Pharmacopoeia (Addyi EP), Addyi JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Addyi USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search